CQ40. What Are Applications and Roles of Ablation?

  • Seigo Kinuya
  • Naoyuki Shigematsu
  • Yasushi Noguchi
  • Tatsuya Higashi


Minute thyroid tissue is known to remain even after total thyroidectomy. The existence of remnant thyroid tissue makes postoperative follow-up by serum thyroglobulin difficult. Furthermore, the possibility of local recurrence from the minute remnant thyroid cannot be denied in high-risk patients. Therefore, for such cases, it is preferable that remnant thyroid tissue that interferes with follow-up and local control be completely removed.


Total Thyroidectomy Thyroid Tissue Differentiate Thyroid Carcinoma Postoperative Recurrence Extrathyroid Extension 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418–428 (RS)PubMedCrossRefGoogle Scholar
  2. 2.
    Sawka AM, Thephamongkhol K, Brouwers M et al (2004) Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89:3668–3676 (SR<RS>)PubMedCrossRefGoogle Scholar
  3. 3.
    Sawka AM, Brierley JD, Tsang RW et al (2008) An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 37:457–480 (SR<RS>)PubMedCrossRefGoogle Scholar
  4. 4.
    Mazzaferri EL (1999) An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 9:421–427 (NR)PubMedCrossRefGoogle Scholar
  5. 5.
    Mazzaferri EL, Kloos RT (2001) Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J clin Endocrinol Metab 86:1447–1463 (NR)PubMedCrossRefGoogle Scholar
  6. 6.
    Robbins RJ, Schlumberger MJ (2005) The evolving role of 131I for the treatment of differentiated thyroid carcinoma. J Nucl Med 46(Suppl 1):28S–37S (NR)PubMedGoogle Scholar
  7. 7.
    Handkiewicz-Junak D, Wloch J, Roskosz J et al (2007) Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. J Nucl Med 48:879–888 (RS)PubMedCrossRefGoogle Scholar
  8. 8.
    Shigematsu N, Takami H, Kubo A (2006) (Text in Japanese). Nihon Ishikai Zasshi 135:1333–1340 (NR)Google Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  • Seigo Kinuya
    • 1
  • Naoyuki Shigematsu
    • 2
  • Yasushi Noguchi
    • 3
  • Tatsuya Higashi
    • 4
  1. 1.Department of Nuclear Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health ScienceKanazawa UniversityKanazawaJapan
  2. 2.Department of RadiologyKeio University School of MedicineTokyoJapan
  3. 3.Department of RadiologyNoguchi Thyroid Clinic and Hospital FoundationBeppuJapan
  4. 4.Shiga Medical Center Research InstituteOtsu-shiJapan

Personalised recommendations